MAPT and Alzheimer disease: We observed that CKD‐504 reduced tau in AD brain organoids treated with vehicle and lysosomal inhibitor, but failed to degrade tau in the presence of proteasomal inhibitor, MG132, showing effects of tau degradation with CKD‐504 are mediated by proteasomal degradation pathway (Figure 4a,b).